International Journal of Medical and Pharmaceutical Research
2025, Volume-6, Issue-4 : 913-923 doi: 10.5281/zenodo.16918469
Original Article
Comparison of Different Doses of Rocuronium Bromide on Intubating Conditions During Endotracheal Intubation in Adults Undergoing Abdominal Surgery
 ,
 ,
Published
Aug. 21, 2025
Abstract

Background: Rocuronium bromide is a widely used non-depolarizing neuromuscular blocking agent for endotracheal intubation. This study aimed to compare the intubating conditions and hemodynamic changes of three different doses of rocuronium bromide during endotracheal intubation.

Methods: This prospective observational study included 60 ASA I-II adult patients (25-45 years) undergoing elective abdominal surgeries, divided into three groups of 20 patients each: Group A (0.6 mg/kg), Group B (0.9 mg/kg), and Group C (1.2 mg/kg). Intubating conditions were assessed at 60 seconds after administration using Cooper's criteria. Heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP) were recorded before induction, after induction, and at 1, 3, and 5 minutes after intubation. Train-of-four (TOF) monitoring was used to assess neuromuscular blockade.

Results: Clinically acceptable intubating conditions (excellent or good) were observed in 0%, 45%, and 100% of patients in Groups A, B, and C, respectively (p<0.001). Mean intubating scores were 3.25±1.07, 5.20±1.67, and 8.35±1.18 in Groups A, B, and C, respectively (p<0.001). After intubation, hemodynamic parameters increased in all groups, with Group A showing the most significant changes (p<0.001). Mean time to loss of TOF was 123.60±3.27, 93.35±5.02, and 61.50±3.85 seconds in Groups A, B, and C, respectively (p<0.001).

Conclusion: Rocuronium bromide at 1.2 mg/kg provides excellent intubating conditions at 60 seconds compared to lower doses. Despite greater hemodynamic fluctuations with increasing doses, all doses demonstrated acceptable hemodynamic stability. Rocuronium can be a suitable alternative when succinylcholine is contraindicated

Recommended Articles
Loading Image...
Volume-6, Issue-4
Citations
1555 Views
144 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved